BioVie (BIVI) Expected to Announce Quarterly Earnings on Tuesday

BioVie (NASDAQ:BIVI) is expected to issue its Q3 2025 quarterly earnings data before the market opens on Tuesday, May 13th. Analysts expect BioVie to post earnings of ($0.32) per share for the quarter.

BioVie (NASDAQ:BIVI) last issued its quarterly earnings results on Tuesday, February 11th. The company reported ($0.46) EPS for the quarter.

BioVie Stock Down 1.3 %

NASDAQ BIVI opened at $1.13 on Tuesday. The company has a market capitalization of $20.76 million, a price-to-earnings ratio of -0.11 and a beta of 0.66. BioVie has a twelve month low of $0.62 and a twelve month high of $7.50. The stock has a fifty day simple moving average of $0.97 and a 200 day simple moving average of $1.88.

Analyst Upgrades and Downgrades

Separately, Brookline Capital Management raised BioVie to a “strong-buy” rating in a research note on Tuesday, March 18th.

BioVie Company Profile

BioVie Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States. Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease, as well as Phase 2 clinical trial for the treatment of Parkinson's disease.